Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Would you add pembrolizumab to enfortumab to further treat a patient with metastatic bladder cancer that progressed on avelumab maintenance after cis/gem?
Related Questions
What is your approach to a patient with muscle invasive bladder cancer getting neoadjuvant gemcitabine/cisplatin who develops significant ototoxicity due to cisplatin after two cycles?
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
Will you now recommend enfortumab and pembrolizumab for most patients with metastatic urothelial carcinoma, regardless of platinum eligibility, based on the EV 302 presentation at ESMO 2023?
Under what circumstances would it be appropriate to offer trimodality therapy (TMT) in muscle-invasive bladder cancer with localized variant histology?
Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?
Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?
Is there a role for single agent immunotherapy in a patient with T2 muscle-invasive bladder cancer without lymph nodes or distant metastasis who declines chemotherapy and cystectomy?
Would you consider a treatment break for a patient with metastatic urothelial carcinoma who achieved a near-complete response to Enfortumab?
Would you offer neoadjuvant chemotherapy prior to trimodality therapy in a fit patient who refuses surgery for muscle-invasive bladder cancer?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
